The effect on surgical success of intravitreal bevacizumab given before pars plana vitrectomy in diabetic patients

Basit Öğe Kaydı
dc.authorscopusid6701346723
dc.authorscopusid35740733300
dc.authorscopusid22978185500
dc.authorscopusid35298889200
dc.authorscopusid23666447600
dc.contributor.authorDo?anay S.
dc.contributor.authorKoç B.
dc.contributor.authorÇankaya C.
dc.contributor.authorDüz C.
dc.contributor.authorBilak S.
dc.date.accessioned2024-08-04T20:01:00Z
dc.date.available2024-08-04T20:01:00Z
dc.date.issued2010
dc.departmentİnönü Üniversitesien_US
dc.description.abstractPurpose: To investigate the effect on surgical success of intravitreal bevacizumab given before pars plana vitrectomy in diabetic patients. Materials and Methods: All patients were divided into two groups: those given bevacizumab before surgery (Group 1; 32 patients) and those not given bevacizumab (Group 2; 50 patients). The groups were compared with regard to the frequencies of retinal tear and active bleeding during surgery, postoperative changes in best corrected visual acuity (BCVA) and intraocular pressure (IOP), postoperative frequencies of retinal detachment and recurrent vitreous hemorrhage (VH), and development of rubeosis. Results: During the surgery, retinal tear was observed in 2 patients (6.3%) from Group 1 and in 4 patients (8%) from Group 2; active bleeding was seen in 2 patients (6.3%) from Group 1 and in 4 patients (8%) from Group 2. After the surgery, retinal detachment was found in 1 patient (3.1%) from Group 1 and in 2 patients (4%) from Group 2; recurrent VH was found in 4 patients (12.5%) from Group 1 and in 14 patients (28%) from Group 2. In the postoperative controls, an increase in IOP was determined in 6 patients (18.8%) from Group 1 and in 9 patients (18%) from Group 2. In the postoperative controls, an increase in the mean BCVA value was determined in 24 patients (75%) from Group 1 and in 32 patients (64%) from Group 2. Conclusion: In the patients with PDR, anti-VEGF (vascular endothelial growth factor) drugs positively influence the surgical success by causing the active new vasculature to be regressed and consequently allowing easy cleaning of the membranes during surgery. Due to the anti-inflammatory and anti-edematous effect of anti-VEGF drugs, better BCVA is obtained after surgery.en_US
dc.identifier.endpage313en_US
dc.identifier.issn1300-1256
dc.identifier.issue4en_US
dc.identifier.scopus2-s2.0-79251574652en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage310en_US
dc.identifier.urihttps://hdl.handle.net/11616/91172
dc.identifier.volume18en_US
dc.indekslendigikaynakScopusen_US
dc.language.isotren_US
dc.relation.ispartofRetina-Vitreusen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBevacizumaben_US
dc.subjectPars plana vitrectomyen_US
dc.subjectProliferative diabetic retinopathyen_US
dc.titleThe effect on surgical success of intravitreal bevacizumab given before pars plana vitrectomy in diabetic patientsen_US
dc.title.alternativeDiyabetik olgularda pars plana vitrektomiden önce uygulanan i?ntravitreal bevacizumabin cerrahi başariya etkisien_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu